Search In this Thesis
   Search In this Thesis  
العنوان
Diagnostic Value Of Serum Leptin As A Tumor Marker In Hepatocellular Carcinoma /
المؤلف
.Elkhososy, Mohammed Ahmed Abdelhalim
هيئة الاعداد
باحث / محمد أحمد عبدالحليم الخصوصي
مشرف / خالدمحمد عبد الوهاب
مشرف / محمد عبدالمعبود محمد
مشرف / محمد مجدي سلامه
الموضوع
Internal medicine.
تاريخ النشر
2019.
عدد الصفحات
132 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الطب الباطني
تاريخ الإجازة
28/8/2019
مكان الإجازة
جامعة عين شمس - كلية الطب - قسم الباطنة العامة
الفهرس
Only 14 pages are availabe for public view

from 132

from 132

Abstract

Hepatocellular Carcinoma (HCC) constitutes one of the most common forms of cancer worldwide, and it holds 3rd place in malignancy related mortality. Eighty percent of liver cancers occur on top of liver cirrhosis. The major risk for cirrhosis is chronic hepatitis B (HBV) and hepatitis C virus (HCV) infection, non alcoholic steatohepatitis (NASH), alcohol abuse. Less common causes include primary biliary cirrhosis, primary sclerosing cholangitis, Hemo-chromatosis, Wilson disease and autoimmune hepatitis.
HCC screening for early HCC diagnosis is the target to allow early intervention with curative treatment recommendations for Child-Pugh stage A and B patients are used by abdominal ultrasound every six months. AFP or other tumour biomarkers (AFP, AFP-L3 and DCP) are not recommended due to less accuracy for early detection of HCC. Stage C cirrhosis is excluded from screening except for transplant candidates.
Leptin is mainly produced in adipose tissue and circulating leptin levels correlate well with the amount of body fat, reflecting energy status. Leptin plays an important role in regulating energy homeostasis, neuroendocrine and immune functions, and glucose, lipid and bone metabolism.
Participants included in this study were classified into the following groups:
Group1: HCC patients without previous therapeutic intervention. This group included 30 patients.
Group2: HCC patients with previous therapeutic intervention. This group included 30 patients.
Group3: End stage chronic liver disease patients without HCC. This group included 15 patients.
Group4: This group included 15 normal person as a control group attending Blood Bank as blood donors.
AS regard serum leptin level, all patients groups(1,2and3) were higher than control (group 4): with median (IQR) 40(37-50), 8( 3-20), 2(1-4)and 1(1-1)ng/ml respectively.
Also, HCC groups (1 and 2) were higher than group 3 (CLD without HCC) with median (IQR) 40(37-50), 8(3-20) and 2 (1-4) ng/ml respectively.
Furthermore, untreated HCC (group 1) was higher than treated HCC (group2) as median (IQR) 40 (37-50) and 8(3-20)ng/ml respectively.
Serum leptin has good sensitivity and specificity in differentiation between cirrhotic patients with or without HCC.
Also it has good sensitivity and specificity in differentiating between untreated HCC and treated HCC patients and it is superior to AFP in the specificity of this differentiation.
Serum leptin can be used as a good screening marker for diagnosis and prognosis of HCC patients.